Phaseline

Companies › Stingray Therapeutics

Stingray Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SR-8541A
ENPP1 inhibitor
ENPP1Phase 1Advanced / Metastatic Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06063681SR-8541APhase 1Advanced / Metastatic Solid TumorOncologyDec 2025

Targets

ENPP1 (1)

Companies with the same targets

Riboscience Colgate Palmolive Inozyme Pharma

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.